| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mesothelioma | 26 | 2023 | 77 | 10.700 |
Why?
|
| Pleural Neoplasms | 21 | 2023 | 62 | 9.580 |
Why?
|
| Lung Neoplasms | 43 | 2023 | 1614 | 9.190 |
Why?
|
| Thoracic Outlet Syndrome | 9 | 2023 | 21 | 6.040 |
Why?
|
| Thoracic Surgical Procedures | 10 | 2023 | 102 | 5.420 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 15 | 2020 | 339 | 5.210 |
Why?
|
| Thymus Neoplasms | 10 | 2019 | 39 | 4.700 |
Why?
|
| Pneumonectomy | 12 | 2022 | 140 | 3.360 |
Why?
|
| Thymoma | 6 | 2019 | 17 | 3.310 |
Why?
|
| Robotic Surgical Procedures | 6 | 2023 | 198 | 3.100 |
Why?
|
| Thymectomy | 5 | 2019 | 24 | 2.370 |
Why?
|
| Ribs | 7 | 2023 | 51 | 2.340 |
Why?
|
| Robotics | 3 | 2023 | 109 | 2.100 |
Why?
|
| Adenocarcinoma | 10 | 2022 | 1001 | 2.010 |
Why?
|
| Neoplasms, Glandular and Epithelial | 4 | 2019 | 40 | 1.810 |
Why?
|
| Neoplasm Staging | 15 | 2022 | 1227 | 1.730 |
Why?
|
| Thoracic Wall | 2 | 2023 | 38 | 1.490 |
Why?
|
| Pleura | 5 | 2018 | 24 | 1.420 |
Why?
|
| Esophagectomy | 3 | 2021 | 64 | 1.380 |
Why?
|
| Biomarkers, Tumor | 8 | 2022 | 1424 | 1.370 |
Why?
|
| Humans | 108 | 2024 | 122432 | 1.330 |
Why?
|
| Thoracic Surgery | 2 | 2021 | 158 | 1.320 |
Why?
|
| Thoracoscopy | 2 | 2021 | 42 | 1.270 |
Why?
|
| Decompression, Surgical | 5 | 2021 | 97 | 1.240 |
Why?
|
| Mediastinal Neoplasms | 2 | 2018 | 41 | 1.210 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2019 | 1118 | 1.210 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2021 | 2030 | 1.140 |
Why?
|
| Neoadjuvant Therapy | 6 | 2023 | 326 | 1.100 |
Why?
|
| B7-H1 Antigen | 4 | 2023 | 102 | 1.060 |
Why?
|
| Esophageal Neoplasms | 6 | 2022 | 355 | 1.060 |
Why?
|
| Surgeons | 3 | 2021 | 244 | 1.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2021 | 1890 | 0.900 |
Why?
|
| Lung | 4 | 2022 | 1476 | 0.820 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2018 | 371 | 0.820 |
Why?
|
| Prognosis | 13 | 2022 | 4489 | 0.790 |
Why?
|
| Cervical Rib | 1 | 2021 | 1 | 0.790 |
Why?
|
| Thoracic Neoplasms | 2 | 2021 | 38 | 0.790 |
Why?
|
| Treatment Outcome | 17 | 2023 | 12041 | 0.760 |
Why?
|
| Antineoplastic Agents | 5 | 2023 | 1680 | 0.730 |
Why?
|
| Racism | 1 | 2021 | 35 | 0.730 |
Why?
|
| Antigens, Neoplasm | 3 | 2018 | 387 | 0.720 |
Why?
|
| Cisplatin | 2 | 2021 | 255 | 0.720 |
Why?
|
| Aged | 25 | 2020 | 18785 | 0.710 |
Why?
|
| Morphine | 1 | 2020 | 88 | 0.700 |
Why?
|
| Sarcopenia | 1 | 2020 | 38 | 0.700 |
Why?
|
| Positron-Emission Tomography | 2 | 2020 | 285 | 0.690 |
Why?
|
| Middle Aged | 27 | 2021 | 25641 | 0.690 |
Why?
|
| Female | 43 | 2024 | 64958 | 0.680 |
Why?
|
| Thoracic Surgery, Video-Assisted | 2 | 2023 | 56 | 0.660 |
Why?
|
| Tumor Microenvironment | 9 | 2024 | 548 | 0.650 |
Why?
|
| Povidone-Iodine | 1 | 2019 | 11 | 0.650 |
Why?
|
| Margins of Excision | 1 | 2019 | 51 | 0.640 |
Why?
|
| Ganglioneuroma | 1 | 2018 | 18 | 0.640 |
Why?
|
| Retrospective Studies | 22 | 2022 | 15856 | 0.640 |
Why?
|
| Surgical Flaps | 1 | 2021 | 205 | 0.630 |
Why?
|
| Aged, 80 and over | 15 | 2020 | 6289 | 0.630 |
Why?
|
| Frailty | 1 | 2020 | 98 | 0.630 |
Why?
|
| Stomach | 1 | 2021 | 274 | 0.620 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2018 | 646 | 0.620 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2019 | 104 | 0.620 |
Why?
|
| Male | 40 | 2021 | 59590 | 0.610 |
Why?
|
| Liposarcoma | 1 | 2018 | 22 | 0.610 |
Why?
|
| Survival Rate | 8 | 2022 | 1997 | 0.600 |
Why?
|
| Hyperthermia, Induced | 1 | 2018 | 45 | 0.600 |
Why?
|
| Deoxycytidine | 1 | 2018 | 78 | 0.600 |
Why?
|
| Venous Thrombosis | 1 | 2020 | 182 | 0.590 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 253 | 0.580 |
Why?
|
| Parapsychology | 1 | 2017 | 1 | 0.570 |
Why?
|
| GPI-Linked Proteins | 1 | 2017 | 95 | 0.570 |
Why?
|
| Radiosurgery | 2 | 2015 | 108 | 0.560 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 161 | 0.560 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2022 | 32 | 0.560 |
Why?
|
| Certification | 1 | 2017 | 69 | 0.550 |
Why?
|
| Genes, erbB-1 | 1 | 2016 | 10 | 0.550 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 99 | 0.550 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2016 | 23 | 0.540 |
Why?
|
| Macrophages, Alveolar | 1 | 2016 | 44 | 0.540 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2015 | 10 | 0.510 |
Why?
|
| Respiratory Tract Fistula | 1 | 2015 | 16 | 0.510 |
Why?
|
| Esophageal Achalasia | 1 | 2016 | 36 | 0.510 |
Why?
|
| Pleural Diseases | 1 | 2015 | 28 | 0.510 |
Why?
|
| Transcriptome | 2 | 2019 | 904 | 0.500 |
Why?
|
| Learning Curve | 1 | 2015 | 52 | 0.490 |
Why?
|
| Castleman Disease | 1 | 2015 | 14 | 0.490 |
Why?
|
| Mediastinal Diseases | 1 | 2015 | 15 | 0.490 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2016 | 193 | 0.490 |
Why?
|
| Laparoscopy | 1 | 2020 | 502 | 0.490 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2014 | 32 | 0.490 |
Why?
|
| Killer Cells, Natural | 3 | 2021 | 326 | 0.490 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2014 | 45 | 0.480 |
Why?
|
| Pulmonary Alveoli | 1 | 2015 | 139 | 0.480 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2016 | 69 | 0.480 |
Why?
|
| Postoperative Complications | 5 | 2017 | 2995 | 0.480 |
Why?
|
| Tumor Burden | 1 | 2015 | 231 | 0.470 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2014 | 7 | 0.470 |
Why?
|
| Radiography | 1 | 2016 | 806 | 0.460 |
Why?
|
| Head and Neck Neoplasms | 1 | 2018 | 468 | 0.460 |
Why?
|
| Neoplasm Invasiveness | 5 | 2019 | 609 | 0.460 |
Why?
|
| Encephalitis | 1 | 2015 | 111 | 0.440 |
Why?
|
| Forced Expiratory Volume | 1 | 2014 | 169 | 0.430 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 152 | 0.430 |
Why?
|
| Adult | 21 | 2021 | 28757 | 0.430 |
Why?
|
| Survival Analysis | 4 | 2017 | 1468 | 0.430 |
Why?
|
| Databases, Factual | 6 | 2018 | 1159 | 0.420 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 340 | 0.420 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2017 | 147 | 0.410 |
Why?
|
| Thoracotomy | 3 | 2019 | 111 | 0.410 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2012 | 9 | 0.400 |
Why?
|
| Disease Management | 2 | 2015 | 513 | 0.400 |
Why?
|
| Education, Medical, Graduate | 2 | 2021 | 507 | 0.390 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 1407 | 0.390 |
Why?
|
| Coronary Artery Bypass | 1 | 2015 | 486 | 0.390 |
Why?
|
| Leiomyosarcoma | 1 | 2011 | 30 | 0.380 |
Why?
|
| Decision Making | 1 | 2016 | 650 | 0.380 |
Why?
|
| Immunotherapy | 5 | 2024 | 658 | 0.380 |
Why?
|
| Cerebellum | 1 | 2015 | 411 | 0.370 |
Why?
|
| Genomics | 3 | 2018 | 1472 | 0.370 |
Why?
|
| Myeloid Cells | 1 | 2011 | 100 | 0.360 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2015 | 425 | 0.360 |
Why?
|
| Cell Line, Tumor | 8 | 2024 | 3293 | 0.360 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 70 | 0.360 |
Why?
|
| Hernia, Obturator | 1 | 2010 | 5 | 0.350 |
Why?
|
| Risk Assessment | 6 | 2021 | 3307 | 0.350 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1674 | 0.350 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 5013 | 0.350 |
Why?
|
| Uterine Neoplasms | 1 | 2011 | 119 | 0.350 |
Why?
|
| Registries | 1 | 2016 | 1368 | 0.340 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2011 | 132 | 0.340 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 872 | 0.340 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 1008 | 0.330 |
Why?
|
| United States | 10 | 2021 | 10490 | 0.320 |
Why?
|
| Dendritic Cells | 4 | 2024 | 404 | 0.320 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 1022 | 0.320 |
Why?
|
| Hepatitis, Viral, Animal | 1 | 2008 | 3 | 0.320 |
Why?
|
| Time Factors | 6 | 2018 | 6181 | 0.320 |
Why?
|
| Clinical Competence | 1 | 2015 | 973 | 0.310 |
Why?
|
| CD11c Antigen | 1 | 2008 | 36 | 0.310 |
Why?
|
| Risk Factors | 7 | 2021 | 9901 | 0.310 |
Why?
|
| Patient Selection | 4 | 2020 | 685 | 0.300 |
Why?
|
| Macrophages | 4 | 2022 | 611 | 0.290 |
Why?
|
| Odds Ratio | 3 | 2017 | 1235 | 0.290 |
Why?
|
| Reoperation | 3 | 2017 | 807 | 0.290 |
Why?
|
| Postoperative Period | 2 | 2019 | 330 | 0.290 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 428 | 0.280 |
Why?
|
| Neoplasm, Residual | 2 | 2017 | 122 | 0.270 |
Why?
|
| Cohort Studies | 5 | 2022 | 4655 | 0.270 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 2080 | 0.260 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2018 | 103 | 0.260 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2023 | 717 | 0.260 |
Why?
|
| Combined Modality Therapy | 4 | 2021 | 1247 | 0.250 |
Why?
|
| Adenoviridae | 1 | 2008 | 637 | 0.250 |
Why?
|
| Neoplasms | 5 | 2024 | 2753 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 1244 | 0.240 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2005 | 137 | 0.240 |
Why?
|
| Neoplasm Transplantation | 3 | 2021 | 375 | 0.230 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 585 | 0.230 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2023 | 19 | 0.220 |
Why?
|
| Facial Nerve | 1 | 2003 | 25 | 0.220 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2003 | 8 | 0.220 |
Why?
|
| Parotid Neoplasms | 1 | 2003 | 15 | 0.220 |
Why?
|
| Proteostasis | 1 | 2023 | 35 | 0.210 |
Why?
|
| Endoribonucleases | 1 | 2023 | 84 | 0.210 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2023 | 145 | 0.210 |
Why?
|
| Soot | 1 | 2022 | 15 | 0.210 |
Why?
|
| CTLA-4 Antigen | 1 | 2023 | 50 | 0.210 |
Why?
|
| Skull Base Neoplasms | 1 | 2003 | 35 | 0.210 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 156 | 0.210 |
Why?
|
| Medical Audit | 1 | 2002 | 100 | 0.200 |
Why?
|
| Young Adult | 5 | 2019 | 8778 | 0.200 |
Why?
|
| Hepatectomy | 1 | 2002 | 122 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 398 | 0.190 |
Why?
|
| Biomimetics | 1 | 2021 | 15 | 0.190 |
Why?
|
| Tomography, Emission-Computed | 1 | 2001 | 43 | 0.190 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2024 | 469 | 0.190 |
Why?
|
| Mice | 12 | 2024 | 17568 | 0.190 |
Why?
|
| Drainage | 1 | 2002 | 254 | 0.180 |
Why?
|
| Situs Inversus | 1 | 2021 | 26 | 0.180 |
Why?
|
| Kartagener Syndrome | 1 | 2021 | 14 | 0.180 |
Why?
|
| Anastomotic Leak | 1 | 2021 | 28 | 0.180 |
Why?
|
| Heterografts | 1 | 2021 | 184 | 0.180 |
Why?
|
| Apoptosis | 4 | 2021 | 1791 | 0.180 |
Why?
|
| Enzyme Inhibitors | 1 | 2023 | 582 | 0.180 |
Why?
|
| Carcinoma | 1 | 2003 | 282 | 0.180 |
Why?
|
| Dissection | 1 | 2020 | 53 | 0.180 |
Why?
|
| Anastomosis, Surgical | 1 | 2021 | 169 | 0.180 |
Why?
|
| Regional Blood Flow | 1 | 2021 | 212 | 0.180 |
Why?
|
| Early Detection of Cancer | 2 | 2021 | 333 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2021 | 559 | 0.170 |
Why?
|
| Pain Measurement | 1 | 2021 | 329 | 0.170 |
Why?
|
| Respiratory System | 1 | 2020 | 96 | 0.170 |
Why?
|
| Frail Elderly | 1 | 2020 | 95 | 0.170 |
Why?
|
| Logistic Models | 2 | 2015 | 1772 | 0.170 |
Why?
|
| Lymphatic Metastasis | 2 | 2018 | 398 | 0.170 |
Why?
|
| National Cancer Institute (U.S.) | 4 | 2020 | 32 | 0.170 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 56 | 0.170 |
Why?
|
| Colorectal Neoplasms | 2 | 2005 | 559 | 0.170 |
Why?
|
| Animals | 15 | 2024 | 33755 | 0.160 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2021 | 506 | 0.160 |
Why?
|
| Triage | 1 | 2020 | 141 | 0.160 |
Why?
|
| Peptides | 2 | 2024 | 798 | 0.160 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 268 | 0.160 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2019 | 68 | 0.160 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 6 | 0.160 |
Why?
|
| Multimodal Imaging | 1 | 2019 | 115 | 0.150 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2019 | 70 | 0.150 |
Why?
|
| Attention | 1 | 2020 | 195 | 0.150 |
Why?
|
| Mutation | 4 | 2024 | 5776 | 0.150 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2018 | 5 | 0.150 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2018 | 12 | 0.150 |
Why?
|
| Pain | 1 | 2021 | 450 | 0.150 |
Why?
|
| Prospective Studies | 3 | 2018 | 5962 | 0.150 |
Why?
|
| Monitoring, Physiologic | 2 | 2017 | 357 | 0.150 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2017 | 16 | 0.150 |
Why?
|
| Biomarkers | 3 | 2022 | 2933 | 0.150 |
Why?
|
| Adolescent | 5 | 2019 | 18970 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 267 | 0.150 |
Why?
|
| Solubility | 1 | 2017 | 133 | 0.150 |
Why?
|
| Tissue Donors | 1 | 2021 | 498 | 0.140 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 269 | 0.140 |
Why?
|
| Interleukin-17 | 1 | 2018 | 119 | 0.140 |
Why?
|
| Proteogenomics | 1 | 2018 | 70 | 0.140 |
Why?
|
| Peptide Fragments | 1 | 2021 | 745 | 0.140 |
Why?
|
| Publication Bias | 1 | 2017 | 11 | 0.140 |
Why?
|
| Pulmonary Artery | 1 | 2021 | 440 | 0.140 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 352 | 0.140 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2016 | 9 | 0.140 |
Why?
|
| Antigen-Antibody Complex | 1 | 2016 | 65 | 0.140 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 323 | 0.140 |
Why?
|
| Clodronic Acid | 1 | 2016 | 4 | 0.140 |
Why?
|
| Genes, Synthetic | 1 | 2016 | 12 | 0.140 |
Why?
|
| Cetuximab | 1 | 2016 | 13 | 0.140 |
Why?
|
| Lung Transplantation | 1 | 2021 | 316 | 0.140 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2016 | 14 | 0.140 |
Why?
|
| Blood Transfusion | 1 | 2019 | 303 | 0.140 |
Why?
|
| Preoperative Period | 1 | 2016 | 83 | 0.140 |
Why?
|
| Uteroglobin | 1 | 2016 | 47 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 289 | 0.140 |
Why?
|
| Macrophage Activation | 1 | 2016 | 62 | 0.130 |
Why?
|
| HLA Antigens | 1 | 2017 | 240 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 397 | 0.130 |
Why?
|
| Maternal-Fetal Relations | 1 | 2016 | 15 | 0.130 |
Why?
|
| Fetal Distress | 1 | 2016 | 12 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2018 | 108 | 0.130 |
Why?
|
| Standard of Care | 1 | 2017 | 129 | 0.130 |
Why?
|
| Absorbable Implants | 1 | 2015 | 24 | 0.130 |
Why?
|
| ROC Curve | 1 | 2017 | 552 | 0.130 |
Why?
|
| Air | 1 | 2015 | 26 | 0.130 |
Why?
|
| Models, Biological | 2 | 2018 | 1438 | 0.130 |
Why?
|
| Bradycardia | 1 | 2016 | 60 | 0.130 |
Why?
|
| Cell Proliferation | 2 | 2021 | 2313 | 0.130 |
Why?
|
| Heart Rate, Fetal | 1 | 2016 | 64 | 0.130 |
Why?
|
| Single-Cell Analysis | 1 | 2018 | 259 | 0.130 |
Why?
|
| Lymph Nodes | 1 | 2017 | 376 | 0.120 |
Why?
|
| Cytokines | 2 | 2022 | 1272 | 0.120 |
Why?
|
| Antibodies, Neoplasm | 1 | 2015 | 59 | 0.120 |
Why?
|
| Efficiency | 1 | 2015 | 57 | 0.120 |
Why?
|
| Biocompatible Materials | 1 | 2015 | 123 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1250 | 0.120 |
Why?
|
| ErbB Receptors | 1 | 2016 | 282 | 0.120 |
Why?
|
| Pneumothorax | 1 | 2016 | 82 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 1084 | 0.120 |
Why?
|
| Abnormalities, Multiple | 1 | 2021 | 974 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 360 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 378 | 0.120 |
Why?
|
| Cell Movement | 1 | 2018 | 839 | 0.120 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 144 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 501 | 0.120 |
Why?
|
| Hospitals, Low-Volume | 1 | 2014 | 30 | 0.110 |
Why?
|
| Interleukin-15 | 2 | 2021 | 95 | 0.110 |
Why?
|
| Hospitals, High-Volume | 1 | 2014 | 35 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 493 | 0.110 |
Why?
|
| Disease Progression | 2 | 2018 | 1990 | 0.110 |
Why?
|
| Checklist | 1 | 2014 | 87 | 0.110 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 1298 | 0.110 |
Why?
|
| Linear Models | 1 | 2015 | 657 | 0.110 |
Why?
|
| Length of Stay | 2 | 2013 | 1271 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2016 | 768 | 0.110 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2015 | 342 | 0.110 |
Why?
|
| Postoperative Care | 1 | 2015 | 291 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 1000 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 214 | 0.110 |
Why?
|
| Propensity Score | 1 | 2014 | 203 | 0.110 |
Why?
|
| Hernia, Diaphragmatic, Traumatic | 1 | 2012 | 9 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2015 | 235 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1102 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 525 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 670 | 0.100 |
Why?
|
| Consensus | 3 | 2020 | 606 | 0.100 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 758 | 0.100 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2021 | 1099 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2017 | 943 | 0.100 |
Why?
|
| Diaphragm | 1 | 2012 | 97 | 0.100 |
Why?
|
| Interleukin-4 | 1 | 2012 | 139 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 2480 | 0.100 |
Why?
|
| Massachusetts | 1 | 2011 | 124 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2021 | 1153 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 3 | 2021 | 1076 | 0.090 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 503 | 0.090 |
Why?
|
| Kidney Neoplasms | 1 | 2015 | 426 | 0.090 |
Why?
|
| Smoking | 1 | 2016 | 1028 | 0.090 |
Why?
|
| Transplantation, Heterologous | 2 | 2021 | 257 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2013 | 307 | 0.090 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 2440 | 0.090 |
Why?
|
| T-Lymphocytes | 2 | 2016 | 1678 | 0.090 |
Why?
|
| Societies, Medical | 1 | 2014 | 673 | 0.090 |
Why?
|
| Delivery, Obstetric | 1 | 2012 | 253 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2016 | 839 | 0.080 |
Why?
|
| Quality of Life | 1 | 2019 | 1913 | 0.080 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2008 | 19 | 0.080 |
Why?
|
| Interleukin-18 | 1 | 2008 | 61 | 0.080 |
Why?
|
| Adenoviridae Infections | 1 | 2008 | 69 | 0.080 |
Why?
|
| Interleukin-12 | 1 | 2008 | 118 | 0.070 |
Why?
|
| Mice, Knockout | 4 | 2018 | 3773 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 3 | 2024 | 4367 | 0.070 |
Why?
|
| Interferon-gamma | 1 | 2008 | 508 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 1710 | 0.060 |
Why?
|
| Fluorouracil | 1 | 2005 | 140 | 0.060 |
Why?
|
| Liver | 3 | 2008 | 1851 | 0.060 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 4285 | 0.060 |
Why?
|
| Inflammation | 1 | 2012 | 1392 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1873 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2005 | 178 | 0.060 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 650 | 0.060 |
Why?
|
| HLA-B Antigens | 1 | 2024 | 30 | 0.060 |
Why?
|
| Antigen Presentation | 1 | 2024 | 107 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2016 | 680 | 0.060 |
Why?
|
| Liver Neoplasms | 2 | 2005 | 1386 | 0.060 |
Why?
|
| Child | 3 | 2017 | 24105 | 0.050 |
Why?
|
| Gadolinium | 1 | 2003 | 102 | 0.050 |
Why?
|
| Carbon | 1 | 2022 | 90 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2003 | 158 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2022 | 70 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2022 | 237 | 0.050 |
Why?
|
| Rats, Nude | 1 | 2001 | 6 | 0.050 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2021 | 16 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 54 | 0.050 |
Why?
|
| Spectrophotometry | 1 | 2001 | 59 | 0.050 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2021 | 71 | 0.050 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2001 | 40 | 0.050 |
Why?
|
| Accreditation | 1 | 2021 | 83 | 0.050 |
Why?
|
| Mortality | 1 | 2002 | 221 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2001 | 126 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 265 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 101 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2021 | 233 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 174 | 0.040 |
Why?
|
| Herpes Simplex | 1 | 2000 | 58 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2024 | 479 | 0.040 |
Why?
|
| Neoplasms, Experimental | 2 | 2016 | 215 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2022 | 374 | 0.040 |
Why?
|
| Immunity | 1 | 2000 | 182 | 0.040 |
Why?
|
| Cell Division | 1 | 2001 | 796 | 0.040 |
Why?
|
| Emergency Treatment | 1 | 2020 | 86 | 0.040 |
Why?
|
| Limb Salvage | 1 | 2020 | 117 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2021 | 359 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 134 | 0.040 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 160 | 0.040 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2018 | 28 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 161 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 186 | 0.040 |
Why?
|
| Thrombolytic Therapy | 1 | 2020 | 204 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 875 | 0.040 |
Why?
|
| Intention | 1 | 2019 | 94 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2002 | 1034 | 0.040 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 790 | 0.040 |
Why?
|
| Thymus Gland | 1 | 2018 | 101 | 0.040 |
Why?
|
| Smad4 Protein | 1 | 2018 | 57 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2018 | 91 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2018 | 333 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2018 | 261 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2016 | 100 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 97 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2000 | 706 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2018 | 263 | 0.030 |
Why?
|
| Systems Biology | 1 | 2016 | 61 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2016 | 75 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 74 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2829 | 0.030 |
Why?
|
| Tissue Adhesions | 1 | 2015 | 30 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2016 | 109 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2018 | 619 | 0.030 |
Why?
|
| Respiration Disorders | 1 | 2015 | 31 | 0.030 |
Why?
|
| CD40 Antigens | 1 | 2015 | 25 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2016 | 1935 | 0.030 |
Why?
|
| Receptors, IgG | 1 | 2015 | 57 | 0.030 |
Why?
|
| Isoantibodies | 1 | 2015 | 71 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 2015 | 74 | 0.030 |
Why?
|
| Rats | 1 | 2001 | 3658 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 239 | 0.030 |
Why?
|
| Monocytes | 1 | 2016 | 347 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 343 | 0.030 |
Why?
|
| Telemedicine | 1 | 2020 | 422 | 0.030 |
Why?
|
| Hypotension | 1 | 2016 | 177 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 352 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 429 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 469 | 0.030 |
Why?
|
| Rupture | 1 | 2012 | 33 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 2012 | 48 | 0.030 |
Why?
|
| Algorithms | 1 | 2019 | 1576 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 671 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 660 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 3452 | 0.020 |
Why?
|
| Pregnancy | 2 | 2016 | 7094 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2007 | 119 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2016 | 2587 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 4511 | 0.020 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2005 | 85 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2005 | 755 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 1822 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2017 | 13817 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2007 | 3075 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 2010 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 2797 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2000 | 980 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 1679 | 0.010 |
Why?
|